Correlation between finger-prick and venous ciclosporin levels: Association with gingival overgrowth and hypertrichosis

Pediatric Nephrology

Volumn 22, Issue 12, 2007, Pages 2111-2118

  Webb, Nicholas J A ^a,d   Coulthard, Malcolm G ^a   Trompeter, Richard S ^a   Fitzpatrick, Margaret M ^a   Stephens, Suzanne ^a   Dudley, Jan ^a   Maxwell, Heather ^a   Waller, Simon ^a   Smith, Graham C ^a   Watson, Alan R ^a   Hughes, David A ^a   Keevil, Brian G ^b   Ellis, Janice S ^c  

^a British Association for Paediatric Nephrology   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Adverse effects; C2 monitoring; Ciclosporin; Finger prick blood sampling

Indexed keywords

AMLODIPINE; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; CYCLOSPORIN D; IMMUNOSUPPRESSIVE AGENT; LEVAMISOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; PREDNISOLONE; RAPAMYCIN; STEROID;

ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; ETHNICITY; EVENING DOSAGE; FEASIBILITY STUDY; FEMALE; FINGER PRICK BLOOD SAMPLING; GINGIVA OVERGROWTH; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTRICHOSIS; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEPHROTIC SYNDROME; PRIORITY JOURNAL; SOUTH ASIA; TANDEM MASS SPECTROMETRY; TOOTH RADIOGRAPHY; TREATMENT DURATION; VEIN PUNCTURE; VENOUS BLOOD;

BLOOD SPECIMEN COLLECTION; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DRUG MONITORING; FEMALE; FINGERS; GINGIVAL DISEASES; HUMANS; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; NEPHROTIC SYNDROME; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 36049003619     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-007-0586-z     Document Type: Article

References (30)

1. 2 monitoring: A European consensus. Transpl Int 18:768-778
2. Levy GA (2001) C2 monitoring strategy for optimising ciclosporin immunosuppression from the Neoral formulation. BioDrugs 15:279-290
3. Buchler M, Johnston A (2005) Seeking optimal prescription of cyclosporine ME. Ther Drug Monit 27:3-6
4. Rinaldi S, Sesto A, Barsotti P, Faraggiana T, Sera F, Rizzoni G (2005) Cyclosporine therapy monitored with abbreviated area under the curve in nephrotic syndrome. Pediatr Nephrol 20:25-29
5. Fujinaga S, Kaneko K, Takada M, Ohtomo Y, Akashi S, Yamashiro Y (2005) Preprandial C2 monitoring of cyclosporine treatment in children with nephrotic syndrome. Pediatr Nephrol 20:1359-1360
6. Nakahata T, Tanaka H, Tsugawa K, Kudo M, Suziki K, Ito E, Waga S (2005) C1-C2 point monitoring of low-dose cyclosporin A given as a single daily dose in children with steroid-dependent relapsing nephrotic syndrome. Clin Nephrol 64:258-263
7. Nozu K, Iijima K, Sakaeda T, Okumura K, Nakanishi K, Yoshikawa N, Honda M, Ikeda M, Matsuo M (2005) Cyclosporin A absorption profiles in children with nephrotic syndrome. Pediatr Nephrol 7:910-913
8. Dobbels F, Van Damme-Lombaert R, Vanhaecke J, De Geest S (2005) Growing pains: Non-adherence with the immunosuppressive regimen in adolescent transplant recipients. Pediatr Transplant 9:381-390
9. David-Neto E, Lemos FB, Furusawa EA, Schwartzman BS, Cavalcante JS, Yagyu EM, Romano P, Ianhez LE (2000) Impact of ciclosporin A pharmacokinetics on the presence of side-effects in pediatric renal transplantation. J Am Soc Nephrol 11:343-349
10. Rateitschak-Pluss EM, Hefti A, Lortscher R, Thiel G (1983) Initial observation that cyclosporin-A induces gingival enlargement in man. J Clin Peridontol 10:237-246
11. Thomason JM, Seymour RA, Ellis JS, Kelly PJ, Parry G, Dark J, Idle JR (1995) Iatrogenic gingival overgrowth in cardiac transplantation. J Peridontol 66:742-746
12. Ellis JS, Seymour RA, Robertson P, Butler TJ, Thomason JM (2001) Photographic scoring of gingival overgrowth. J Clin Peridontol 28:81-85
13. Thomason JM, Seymour RA, Rawlins MD (1992) Incidence and severity of phenytoin-induced gingival overgrowth in epileptic patients in general medical practice. Community Dent Oral Epidemiol 20:288-291
14. Thomas DW, Newcombe RG, Osborne G (2000) Risk factors in the development of cyclosporine-induced gingival overgrowth. Transplantation 70:552-556
15. Thomas DW, Baboolal K, Subramanian N, Newcombe RG (2001) Cyclosporin A-induced gingival overgrowth is unrelated to allograft function in renal transplant recipients. J Clin Peridontol 28:706-709
16. Thomason JM, Seymour RA, Ellis JS (2005) Risk factors for gingival overgrowth in patients medicated with ciclosporin in the absence of calcium channel blockers. J Clin Peridontol 32:273-279
17. Webb NJ, Roberts D, Preziosi R, Keevil BG (2005) Finger prick blood samples can be used to accurately measure tacrolimus levels by tandem mass spectrometry. Pediatr Transplant 9:729-733
18. Merton G, Jones K, Lee M, Johnston A, Holt DW (2000) Accuracy of cyclosporine measurements made in capillary blood samples obtained by skin puncture. Ther Drug Monit 22:594-598
19. Woods K, Douketis JD, Schnurr T, Kinnon K, Powers P, Crowther MA (2004) Patient preferences for capillary vs venous INR determination in an anticoagulation clinic: A randomized controlled trial. Thromb Res 114:161-165
20. Keevil BG, Tierney DP, Cooper DP, Morris MR, Machaal A, Yonan N (2002) Simultaneous and rapid analysis of ciclosporin A and creatinine in finger prick blood samples using liquid chromatography tandem mass spectrometry and its application to C2 monitoring. Ther Drug Monit 24:757-767
21. Yonan N, Martyszuk R, Machaal A, Baynes A, Keevil BG (2006) Monitoring of cyclosporin levels in transplant recipients using self administered finger prick sampling. Clin Transplant 20:221-225
22. Ferriman D, Gallwey JD (1961) Clinical measurement of body hair growth in women. J Clin Endocrinol Metab 21:1440-1447
23. Hollis S (1996) Analysis of method comparison studies. Ann Clin Biochem 33:1-4
24. Pape L, Lehnhardt A, Latta K, Ehrich JH, Offner G (2003) Cyclosporin A monitoring by 2-h levels: Preliminary target levels in stable pediatric kidney transplant recipients. Clin Transplant 17:546-548
25. Pape L, Ehrich JH, Offner G (2004) Advantages of cyclosporine A using 2-h levels in pediatric kidney transplantation. Pediatr Nephrol 19:1035-1038
26. Trompeter R, Filler G, Webb NJ, Watson AR, Milford DV, Tyden G, Grenda R, Janda J, Hughes D, Ehrich JH, Klare B, Zacchello G, Brekke IB, McGraw M, Perner F, Ghio L, Balzar E, Friman S, Gusmano R, Stolpe J (2002) Randomised multicentre study comparing tacrolimus with cyclosporin in renal transplantation. Pediatr Nephrol 17:141-149
27. Mahalati K, Belitsky P, Sketris I, West K, Panek R (1999) Neoral monitoring by simplified sparse sampling area under the concentration curve: Its relationship to acute rejection and cyclosporine nephrotoxicity after kidney transplantation. Transplantation 68:55-62
28. Mahalati K, Belitsky P, West K, Kiberd B, Fraser A, Sketris I, Macdonald AS, McAlister V, Lawen J (2001) Approaching the therapeutic window for cyclosporine in kidney transplantation: A prospective study. J Am Soc Nephrol 12:828-833
29. Weber LT, Armstrong VW, Shipkova M, Feneberg R, Wiesel M, Mehls O, Zimmerhackl LB, Lellerich M, Tonshoff B, Members of the German Study Group on Pediatric Renal Transplantation (2004) Cyclosporin A absorption in pediatric renal transplant recipients predicts the risk of acute rejection. Ther Drug Monit 26:415-424
30. Kyllönen LE, Salmela KT (2006) Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: A prospective randomized single-center pilot study. Transplantation 81:1010-1015